Inhibitory activities of acteoside, isoacteoside, and its structural constituents against protein glycation in vitro

Yuh Hwa Liu, Yeh Lin Lu, Chuan Hsiao Han, Wen Chi Hou

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Advanced glycation end products (AGE) are substances that can induce insulin resistance in adipocyte, hepatocyte and muscle cells. This resistance correlates highly with cardiovascular disease and diabetic complications. Acteoside (A), a phenylethanoid glycoside, is an active compound in several plants and traditional herbal medicines. Acteoside, its structural isomer, isoacteoside (I), and their constituents, caffeic acid (C) and 3,4-dihydroxyphenylethanol (D), were used in the study to investigate the inhibitory activity against AGE formations in vitro. Results: AGE formations were detected by anti-(Nε-(carboxymethyl)lysine (anti-CML), using bovine serum albumin (BSA)/glucose (glc) and BSA/galactose (gal) as models, or by anti-argpyrimidine (anti-AP), using BSA/methylglyoxal (MGO) as models. It was found that A, I, C, or D, each at 5 mM, could attenuate the CML formations detected by ELISA in the BSA/gal model of a 3-day or 5-day reaction, and showed significant differences (P <0.01 or P <0.001) compared to the control. However, these compounds showed a minor effect after a 7-day incubation. It was also found that C or D could lower the CML formations in the BSA/glc model and showed significant differences (P <0.05 or P <0.01) compared to the control after a 3-day, 5-day and 7-day reaction. It was found that A, I, C, or D, each at 0.5 mM or 5 mM, could attenuate the AP formations in the BSA/MGO model of a 3-day reaction and showed significant differences (P <0.001) compared to the control. Conclusions: The results suggest the potential anti-glycation activities of A and I in vitro may apply to cell models at higher glucose concentrations or to diabetic animal models, and need further investigation.

Original languageEnglish
JournalBotanical Studies
Volume54
Issue number1
DOIs
Publication statusPublished - Aug 19 2013

Fingerprint

glycation
bovine serum albumin
proteins
galactose
glucose
complications (disease)
herbal medicines
caffeic acid
adipocytes
insulin resistance
myocytes
cardiovascular diseases
hepatocytes
isomers
glycosides
lysine
animal models
enzyme-linked immunosorbent assay
advanced glycation end products

Keywords

  • 3'4'-dihydroxyphenylethanol
  • Acteoside
  • Advanced glycation endproducts
  • Argpyrimidine
  • Cafeic acid
  • Isoacteoside
  • Methylglyoxal
  • N-(carboxymethyl)lysine

ASJC Scopus subject areas

  • Plant Science

Cite this

Inhibitory activities of acteoside, isoacteoside, and its structural constituents against protein glycation in vitro. / Liu, Yuh Hwa; Lu, Yeh Lin; Han, Chuan Hsiao; Hou, Wen Chi.

In: Botanical Studies, Vol. 54, No. 1, 19.08.2013.

Research output: Contribution to journalArticle

@article{c5c5fc3dda774ef8b193331996d40925,
title = "Inhibitory activities of acteoside, isoacteoside, and its structural constituents against protein glycation in vitro",
abstract = "Background: Advanced glycation end products (AGE) are substances that can induce insulin resistance in adipocyte, hepatocyte and muscle cells. This resistance correlates highly with cardiovascular disease and diabetic complications. Acteoside (A), a phenylethanoid glycoside, is an active compound in several plants and traditional herbal medicines. Acteoside, its structural isomer, isoacteoside (I), and their constituents, caffeic acid (C) and 3,4-dihydroxyphenylethanol (D), were used in the study to investigate the inhibitory activity against AGE formations in vitro. Results: AGE formations were detected by anti-(Nε-(carboxymethyl)lysine (anti-CML), using bovine serum albumin (BSA)/glucose (glc) and BSA/galactose (gal) as models, or by anti-argpyrimidine (anti-AP), using BSA/methylglyoxal (MGO) as models. It was found that A, I, C, or D, each at 5 mM, could attenuate the CML formations detected by ELISA in the BSA/gal model of a 3-day or 5-day reaction, and showed significant differences (P <0.01 or P <0.001) compared to the control. However, these compounds showed a minor effect after a 7-day incubation. It was also found that C or D could lower the CML formations in the BSA/glc model and showed significant differences (P <0.05 or P <0.01) compared to the control after a 3-day, 5-day and 7-day reaction. It was found that A, I, C, or D, each at 0.5 mM or 5 mM, could attenuate the AP formations in the BSA/MGO model of a 3-day reaction and showed significant differences (P <0.001) compared to the control. Conclusions: The results suggest the potential anti-glycation activities of A and I in vitro may apply to cell models at higher glucose concentrations or to diabetic animal models, and need further investigation.",
keywords = "3'4'-dihydroxyphenylethanol, Acteoside, Advanced glycation endproducts, Argpyrimidine, Cafeic acid, Isoacteoside, Methylglyoxal, N-(carboxymethyl)lysine",
author = "Liu, {Yuh Hwa} and Lu, {Yeh Lin} and Han, {Chuan Hsiao} and Hou, {Wen Chi}",
year = "2013",
month = "8",
day = "19",
doi = "10.1186/1999-3110-54-6",
language = "English",
volume = "54",
journal = "Botanical Studies",
issn = "1817-406X",
publisher = "Academia Sinica",
number = "1",

}

TY - JOUR

T1 - Inhibitory activities of acteoside, isoacteoside, and its structural constituents against protein glycation in vitro

AU - Liu, Yuh Hwa

AU - Lu, Yeh Lin

AU - Han, Chuan Hsiao

AU - Hou, Wen Chi

PY - 2013/8/19

Y1 - 2013/8/19

N2 - Background: Advanced glycation end products (AGE) are substances that can induce insulin resistance in adipocyte, hepatocyte and muscle cells. This resistance correlates highly with cardiovascular disease and diabetic complications. Acteoside (A), a phenylethanoid glycoside, is an active compound in several plants and traditional herbal medicines. Acteoside, its structural isomer, isoacteoside (I), and their constituents, caffeic acid (C) and 3,4-dihydroxyphenylethanol (D), were used in the study to investigate the inhibitory activity against AGE formations in vitro. Results: AGE formations were detected by anti-(Nε-(carboxymethyl)lysine (anti-CML), using bovine serum albumin (BSA)/glucose (glc) and BSA/galactose (gal) as models, or by anti-argpyrimidine (anti-AP), using BSA/methylglyoxal (MGO) as models. It was found that A, I, C, or D, each at 5 mM, could attenuate the CML formations detected by ELISA in the BSA/gal model of a 3-day or 5-day reaction, and showed significant differences (P <0.01 or P <0.001) compared to the control. However, these compounds showed a minor effect after a 7-day incubation. It was also found that C or D could lower the CML formations in the BSA/glc model and showed significant differences (P <0.05 or P <0.01) compared to the control after a 3-day, 5-day and 7-day reaction. It was found that A, I, C, or D, each at 0.5 mM or 5 mM, could attenuate the AP formations in the BSA/MGO model of a 3-day reaction and showed significant differences (P <0.001) compared to the control. Conclusions: The results suggest the potential anti-glycation activities of A and I in vitro may apply to cell models at higher glucose concentrations or to diabetic animal models, and need further investigation.

AB - Background: Advanced glycation end products (AGE) are substances that can induce insulin resistance in adipocyte, hepatocyte and muscle cells. This resistance correlates highly with cardiovascular disease and diabetic complications. Acteoside (A), a phenylethanoid glycoside, is an active compound in several plants and traditional herbal medicines. Acteoside, its structural isomer, isoacteoside (I), and their constituents, caffeic acid (C) and 3,4-dihydroxyphenylethanol (D), were used in the study to investigate the inhibitory activity against AGE formations in vitro. Results: AGE formations were detected by anti-(Nε-(carboxymethyl)lysine (anti-CML), using bovine serum albumin (BSA)/glucose (glc) and BSA/galactose (gal) as models, or by anti-argpyrimidine (anti-AP), using BSA/methylglyoxal (MGO) as models. It was found that A, I, C, or D, each at 5 mM, could attenuate the CML formations detected by ELISA in the BSA/gal model of a 3-day or 5-day reaction, and showed significant differences (P <0.01 or P <0.001) compared to the control. However, these compounds showed a minor effect after a 7-day incubation. It was also found that C or D could lower the CML formations in the BSA/glc model and showed significant differences (P <0.05 or P <0.01) compared to the control after a 3-day, 5-day and 7-day reaction. It was found that A, I, C, or D, each at 0.5 mM or 5 mM, could attenuate the AP formations in the BSA/MGO model of a 3-day reaction and showed significant differences (P <0.001) compared to the control. Conclusions: The results suggest the potential anti-glycation activities of A and I in vitro may apply to cell models at higher glucose concentrations or to diabetic animal models, and need further investigation.

KW - 3'4'-dihydroxyphenylethanol

KW - Acteoside

KW - Advanced glycation endproducts

KW - Argpyrimidine

KW - Cafeic acid

KW - Isoacteoside

KW - Methylglyoxal

KW - N-(carboxymethyl)lysine

UR - http://www.scopus.com/inward/record.url?scp=84886420837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886420837&partnerID=8YFLogxK

U2 - 10.1186/1999-3110-54-6

DO - 10.1186/1999-3110-54-6

M3 - Article

AN - SCOPUS:84886420837

VL - 54

JO - Botanical Studies

JF - Botanical Studies

SN - 1817-406X

IS - 1

ER -